StreetInsider.com News Articles

Hims & Hers chief accounting officer to resign in October

Fri, 17 Jul 2026 16:17:31 -0400

Hims & Hers Health (NYSE: HIMS) announced that Irene Becklund, its Chief Accounting Officer and Principal Accounting Officer, has informed the company of her intention to resign, effective October 9, 2026.

Becklund has served as Chief Accounting Officer since April 2025 and as Principal Accounting Officer since November 2021. She indicated that her resignation is not the result of any dispute or disagreement with the company's accounting principles, practices, financial statements, or disclosures.

The company has entered into an advisory agreement with Becklund, effective October 10, 2026, under which she will continue to support the company until July 10, 2027.

Hims & Hers chief accounting officer to resign in October

Fri, 17 Jul 2026 16:17:31 -0400

The company has entered into an advisory agreement with Becklund, effective October 10, 2026, under which she will continue to support the company until July 10, 2027.

Hims & Hers CAO Irene Becklund to depart in October 2026

Fri, 17 Jul 2026 16:17:10 -0400

Hims & Hers Health, Inc. (NYSE: HIMS) announced that Chief Accounting Officer Irene Becklund will leave the company effective October 9, 2026, after more than seven years with the organization.

Following her departure, Becklund will serve as an advisor for several months to assist with the transition. CFO Yemi Okupe will assume the CAO responsibilities on an interim basis while the company conducts a search for a permanent replacement.

Becklund joined Hims & Hers in 2019 as its first Controller. During her tenure, she was involved in the company's IPO, strategic acquisitions, and international expansion, and helped build its financial reporting and

Hims & Hers CAO Irene Becklund to depart in October 2026

Fri, 17 Jul 2026 16:17:10 -0400

Hims & Hers Health, Inc. (NYSE: HIMS) announced that Chief Accounting Officer Irene Becklund will leave the company effective October 9, 2026, after more than seven years with the organization.

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Fri, 17 Jul 2026 16:17:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of CAO in the interim.

"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Fri, 17 Jul 2026 16:17:00 -0400

"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Fri, 17 Jul 2026 16:17:00 -0400

"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

Fri, 17 Jul 2026 16:17:00 -0400

"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and

Form 8-K Hims & Hers Health, Inc. For: Jul 13

Fri, 17 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26784471.html

Form 8-K Hims & Hers Health, Inc. For: Jul 13

Fri, 17 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26784471.html

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Mon, 13 Jul 2026 16:05:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Mon, 13 Jul 2026 16:05:00 -0400

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Mon, 13 Jul 2026 16:05:00 -0400

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Mon, 13 Jul 2026 16:05:00 -0400

Truist Reiterates Hold Rating on Hims and Hers (HIMS)

Thu, 09 Jul 2026 10:24:19 -0400

Truist Securities analyst Jailendra Singh reiterated a Hold rating and $23.00 price target on Hims and Hers (NYSE: HIMS).

The analyst commented: "Our June Card Data suggest HIMS is highly likely to deliver a 2Q26 revenue beat and raise, even before incorporating any potential contribution from the Eucalyptus transaction. Notably, a portion of the revenue upside could flow through to EBITDA, helping ease investor concerns around the ramp implied in the company’s 2H26 EBITDA outlook. That said, the recent appreciation in HIMS shares appears increasingly tied to enthusiasm around the potential opportunity around peptides. Investor focus is now squarely on the

Hims and Hers (HIMS) PT Raised to $37 at BofA Securities

Thu, 09 Jul 2026 05:12:41 -0400

BofA Securities analyst Allen Lutz raised the price target on Hims and Hers (NYSE: HIMS) to $37.00 (from $36.00) while maintaining a Neutral rating.

The analyst comments "We see emerging signs that retention of new oral Wegovy members could be softer than some expect, supporting our prior view that the implied 2H EBITDA ramp will be difficult to achieve. HIMS’ initial oral Wegovy launch in April/May was incredibly strong (HIMS launched around April 1), but customers were relatively flat m/m in June per BSM credit/debit card data (Exhibit 2). Importantly, peer Ro launched oral Wegovy 2-3 months ahead of HIMS and

Hims and Hers (HIMS) PT Raised to $37 at BofA Securities

Thu, 09 Jul 2026 05:12:41 -0400

BofA Securities analyst Allen Lutz raised the price target on Hims and Hers (NYSE: HIMS) to $37.00 (from $36.00) while maintaining a Neutral rating.

Form 4 Hims & Hers Health, Inc. For: Jul 06 Filed by: Okupe Oluyemi

Tue, 07 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260707/26742037.html

Form 4 Hims & Hers Health, Inc. For: Jul 06 Filed by: Okupe Oluyemi

Tue, 07 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260707/26742037.html

Form 144 Hims & Hers Health, Inc. Filed by: Okupe Oluyemi

Mon, 06 Jul 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260706/26736941.html

Form 144 Hims & Hers Health, Inc. Filed by: Okupe Oluyemi

Mon, 06 Jul 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260706/26736941.html

Hims & Hers units enter $400M receivables deal with JPMorgan

Wed, 01 Jul 2026 17:04:04 -0400

Subsidiaries of Hims & Hers Health, Inc. (NYSE: HIMS) entered into a receivables purchase agreement with JPMorgan Chase Bank, N.A. on July 1, 2026, according to a regulatory filing.

XeCare LLC and Apostrophe Pharmacy LLC, both subsidiaries of Hims & Hers, signed a Master Receivables Purchase Agreement that allows them to sell eligible receivables to JPMorgan Chase for cash, at a value equal to the receivable balance minus an applicable purchase discount. JPMorgan Chase retains sole discretion to decline any offered receivables.

The agreement carries a $400 million facility limit and an initial term of 364 days. It may be extended an

Form 8-K Hims & Hers Health, Inc. For: Jun 26

Wed, 01 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26721906.html

Form 8-K Hims & Hers Health, Inc. For: Jun 26

Wed, 01 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26721906.html

Hims and Hers (HIMS) PT Raised to $36 at BofA Securities, 'This update is negative for the HIMS'

Wed, 01 Jul 2026 13:08:11 -0400

BofA Securities analyst Allen Lutz raised the price target on Hims and Hers (NYSE: HIMS) to $36.00 (from $25.00) while maintaining a Neutral rating.

The analyst comments "This update is negative for the HIMS peptide optionality narrative. The initial FDA move to remove various wellness peptides from the Category 2 restricted list and schedule reviews were positive for HIMS given the potentially large addressable market for peptides. While not a final determination, the FDA recommendation lowers the probability that the 7 peptides set for PCAC review in July will clear the hurdle to be added to the 503A Bulk List. The